BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ('Tharimmune' or the 'Company'), a clinical-stage biotechnology ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

This confirms the clinical impression of lichen planus. Lichen planus (LP) is an inflammatory, pruritic, papulosquamous skin disease. This papulosquamous disease may also involve the hair follicle ...

suggestions given during trance may help decrease skin pain and pruritus, intervene in psychosomatic aspects of skin diseases, and lead to the resolution of some skin diseases, including verruca ...

When people think about kidney disease, they often focus on its role in filtering blood, managing fluid levels, and balancing ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

The following is a summary of “Assessing disease control in patients with atopic dermatitis by using the atopic dermatitis ...

Mirum Pharmaceuticals, Inc. today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November ...